Insider Selling: Boston Scientific Co. (NYSE:BSX) EVP Sells 6,983 Shares of Stock

Boston Scientific Co. (NYSE:BSX - Get Free Report) EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Monday, July 1st. The shares were sold at an average price of $77.30, for a total value of $539,785.90. Following the sale, the executive vice president now directly owns 42,908 shares of the company's stock, valued at approximately $3,316,788.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Wendy Carruthers also recently made the following trade(s):

• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39.

Boston Scientific Stock Up 0.2 %

Boston Scientific stock traded up $0.14 on Tuesday, hitting $76.55. 3,321,824 shares of the stock traded hands, compared to its average volume of 6,274,667. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $77.99. The firm has a market cap of $112.30 billion, a P/E ratio of 64.33, a price-to-earnings-growth ratio of 2.65 and a beta of 0.78. The business's fifty day simple moving average is $75.01 and its 200 day simple moving average is $67.81. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The firm had revenue of $3.86 billion for the quarter, compared to analysts' expectations of $3.68 billion. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BSX. UBS Group increased their target price on Boston Scientific from $74.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Robert W. Baird boosted their target price on Boston Scientific from $79.00 to $84.00 and gave the stock an "outperform" rating in a research report on Thursday, April 25th. Evercore ISI increased their price target on shares of Boston Scientific from $78.00 to $81.00 and gave the company an "outperform" rating in a research report on Tuesday. Raymond James boosted their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a "strong-buy" rating in a report on Thursday, April 25th. Finally, The Goldman Sachs Group initiated coverage on shares of Boston Scientific in a report on Thursday, May 30th. They set a "buy" rating and a $90.00 target price on the stock. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $77.41.

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently modified their holdings of BSX. Eagle Bay Advisors LLC raised its position in Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock worth $25,000 after buying an additional 309 shares during the last quarter. First Foundation Advisors purchased a new stake in Boston Scientific during the 1st quarter valued at $25,000. Bruce G. Allen Investments LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at $28,000. RiverPark Advisors LLC purchased a new position in shares of Boston Scientific in the 1st quarter worth $30,000. Finally, Northwest Investment Counselors LLC purchased a new stake in Boston Scientific during the first quarter valued at $31,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.